On December 22, 2025, the news has been confirmed of Samsung Biologics to Buy US Drug Plant which is going to be its first US drug production facility from GSK plc for $280 million in order to reduce risks of the tariffs by the Trump administration, with plans for more investments.
Samsung Biologics America Inc., which is the company’s US unit, is taking over a 100% stake when it comes to Human Genome Sciences Inc., located in Rockville, Maryland. The deal is anticipated to be closed by the end of Q1 of 2026.
With Samsung Biologics to Buy US Drug Plant, the acquisition is all set to raise the total capacity of Samsung Biologics by 60,000 liters to 845,000 liters, thereby cementing its worldwide leader position.
The South Korean company is looking to make additional investments so as to expand the capacity of the site and also upgrade the technology in order to further support a more resilient U.S. supply chain when it comes to critical biologic medicines.
According to John Rim, the CEO and President of Samsung Biologics, this landmark acquisition is indeed a testament to their unwavering commitment so as to advance their global healthcare and, at the same time, bolster their manufacturing capabilities across the US.
The statement further added that the investment is going to help them deepen their collaboration with federal, state, and local stakeholders to best serve their customers as well as partners while making sure of a dependable and stable supply of life-saving therapeutics.
It is worth noting that the takeover is all set to enable Samsung Biologics to sell product across the U.S. without tariffs as the company looks to use the facility for drugs when it comes to the largest medical market in the world.
As per one of the company officials, they are now positioned to proactively address the uncertainties pertaining to U.S. tariff policies, decrease the supply chain risks that stem from future policy changes, and upgrade their responsiveness as well as flexibility for North American customers.
Notably, Samsung Biologics goes on to generate 38.8% of its overall sales from the US.
As per the present deal with Washington, tariffs on US imports when it comes to South Korean pharmaceuticals are not going to be any greater than 15%. While the rates for specific items such as biosimilars as well as biopharmaceuticals have not been finalized.
The competitors of Samsung Biologics, like Lonza from Switzerland and Fujifilm from Japan, operate production facilities across the US amid the prolonged uncertainty related to the Trump administration tariffs.
Interestingly, the acquisition is most likely to help Samsung Biologics get more benefit from a U.S. national security measure, which goes on to restrict the usage of biotechnology equipment as well as services tied to entities that are deemed national security risks in federally funded research and manufacturing, sources from the industry said.
While the BIOSECURE Act does not name any specific countries or companies, industry officials as well as the analysts opine that it is likely to reshape the global outsourcing patterns when it comes to pharmaceutical manufacturing, especially in the contract development and manufacturing segment, where apparently, the Chinese providers have played a massive role.
Analysts widely go on to anticipate that WuXi AppTec, which is the largest and the world’s second-largest CDMO from China, could as well be included in the next update by the Pentagon of its Section 1260H list of entities that are deemed to pose supply chain or national security risks, which is due as early as January 2026.
Notably. Major pharmaceutical companies are anticipated to look out for other suppliers like Samsung Biologics, Lonza, and Fujifilm, said the industry sources.
As per an analyst from Korea Investment & Securities Co. in Seoul, Wi Hae Joo, big pharma favors dual sourcing. Entry by Samsung Biologics to the US is a major event for expanding its order base.
Due to the acquisition of the GSK facility, Samsung Biologics went on to announce a total of $828 million in three orders coming from the European pharmaceutical makers.
All those deals have indeed increased the orders by Samsung Biologics to a record of 6.8 trillion won, which is equivalent to $4.6 billion so far in 2025, which is, interestingly, 26.1% higher than the total figure for 2024. The company anticipates sales in 2025 to rise almost 30% to around 5.9 trillion won.
